THE EFFECT OF CONTINUED ADMINISTRATION OF SUBLINGUAL HEPARIN ON THE FAT TOLERANCE TEST
- THE EFFECT OF SUBLINGUAL HEPARIN ON LIPOPROTEIN DISTRIBUTION IN ATHEROSCLEROSIS. Biancani, G. // Angiology;Apr1961, Vol. 12 Issue 4, p119
Focuses on the capability of sublingual heparin in restoring the distribution of lipoprotein in the body in the treatment of atherosclerosis. Cause of atherosclerosis; Importance of the clearing factor of the heparin in its capacity in treating atherosclerosis; Developments in the heparin therapy.
- Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations. Leong, Wendy; Hoppensteadt, Debra A. // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p293
This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.
- The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Jacques Chanard; Sylvie Lavaud; Hervé Maheut; Isabelle Kazes; Fabien Vitry; Philippe Rieu // Nephrology Dialysis Transplantation;Jun2008, Vol. 23 Issue 6, p2003
Background. The AN69 ST haemodialysis membrane, a new membrane resulting from coating polyethyleneimine upon the polyacrylonitrile surface, binds heparin. In patients at risk of bleeding, a pilot study has demonstrated the efficient anticoagulant effect of this heparin-coated membrane. Study...
- THE EFFECT OF HEPARIN ON CHOLESTEROL PARTITION, LIPOPROTEINS AND ATHEROSCLEROSIS IN EXPERIMENTAL HYPERCHOLESTEROLEMIA. Moses, Campbell; Rhodes, Grace L. // Angiology;Oct1954, Vol. 5 Issue 5, p429
Investigates the effect of heparin on cholesterol partition, lipoproteins and atherosclerosis in experimental hypercholesterolemia. Absence of significant reduction in aortic atherosclerosis in the blood fractions; Failure of heparin to retard the development of atherosclerosis; Impact of high...
- Secondary Prophylaxis with Warfarin for Venous Thromboembolism. Büller, Harry R.; Prins, Martin H. // New England Journal of Medicine;8/14/2003, Vol. 349 Issue 7, p702
Editorial. Offers an editorial on the two phases in the treatment of patients with symptomatic venous thromboembolism. Therapy that consists of either subcutanous low-molecular-weight heparin or intravenous unfractionated heparin; Phase involving oral vitamin K antagonists such as warfarin;...
- Prophylaxis for Thromboembolism in Hospitalized Medical Patients. Francis, Charles W. // New England Journal of Medicine;4/5/2007, Vol. 356 Issue 14, p1438
The article discusses whether an older man who presented to the hospital with fever, cough, and dyspnea should receive thromboprophylaxis. The patient exhibited risk factors for venous thromboembolism. Various treatments for venous thrombosis are described, including nonpharmacologic therapies...
- Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital. Xu, Huimin; Cai, Hongwen; Qian, Zhongshu; Xu, Geng; Yan, Xiaofeng; Dai, Haibin // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p118
Background: Low-molecular-weight heparins (LMWHs) are safe and effective anticoagulant options for cardiovascular patients when applied as body weight-adjusted doses. However, there are some barriers that make it difficult to implement weight-adjusted doses in clinical practice. Therefore, it is...
- Treatment of venous thromboembolism: duration and new options. Huisman, Menno V. // Hematology Journal;2004 Supplement 3, Vol. 5, pS24
Studies the treatment of venous thromboembolism. Initial treatment of choice; Evidence for the need of heparin; Optimal duration of anticoagulant therapy; Management of patients with an increased risk of recurrence.
- Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. Wong, Graham C.; Giugliano, Robert P.; Antman, Elliott M. // JAMA: Journal of the American Medical Association;1/15/2003, Vol. 289 Issue 3, p331
Context: Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent. Objective: To systematically summarize the clinical data on the efficacy and safety of LMWHs compared with unfractionated heparin across the...